- Details
- At the 2021 ASCO GU Cancers Symposium, Dr Robert Motzer and colleagues presented the results of the CLEAR study examining first-line lenvatinib and everolimus or lenvatinib and pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma and concurrent with the presentation, CLEAR was published in the New England Journal of Medicine. In this UroToday Journal Club, Christopher Wall...
|
- Details
- The combination of lenvatinib and pembrolizumab in the CLEAR trial was found to significantly improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) as first-line therapy for patients with advanced renal cell carcinoma (RCC). CLEAR was a large randomized Phase 3 trial comparing lenvatinib in combination with pembrolizumab versus lenvatinib with everolimus...
|
- Details
- In this conversation, Rana McKay and Andrea Apolo highlight several studies presented during the ASCO 2021 Annual Meeting on combination therapeutic options for advanced renal cell carcinoma (RCC). Dr. Apolo expands on several studies she highlighted in her presentation and where these treatment options fit into the treatment landscape of advanced RCC potentially enhancing the immune effect of imm...
|
- Details
- Petros Grivas, MD, PhD and Andrea Apolo, MD highlight results from a pooled analysis of a landmark phase I dose-escalation study and 7 subsequent expansion cohorts. In this study combinations of cabozantinib and nivolumab (CaboNivo) and cabozantinib, nivolumab, and ipilimumab (CaboNivoIpi) demonstrated promising efficacy and safety in a dose-escalation phase I study among patients with metastatic...
|
- Details
- The SWOG 1500 trial is a randomized phase II trial and studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of tumor cells by blocki...
|
- Details
- In this episode of Kidney Cancer Today, Bradley McGregor joins Monty Pal and Jaime Landman to speak about the major practice-changing studies that have come out over the past year in the frontline setting and the evolution of therapy in the renal cell carcinoma space. Biographies: Bradley McGregor, MD, Clinical Director, Senior Physician, Instructor in Medicine, Lank Center for Genitourinary Oncol...
|
- Details
- Alicia Morgans and David Braun discuss his innovative research in metastatic kidney cancer which focuses on understanding and improving immunotherapies in kidney cancer. His work utilizes immunogenomic approaches to generate mechanisms of response and resistance to existing immunotherapies. He is working to develop novel immune-based treatments. David’s key talking points are driven from the thoug...
|
- Details
- Tian Zhang, MD and Monty Pal, MD review first-line therapy options for metastatic renal cell carcinoma (mRCC), including immunotherapy- based ipilimumab, nivolumab, pembrolizumab, axitinib, as well as avelumab/axitinib combinations and cabozantinib monotherapy. Tian continues focusing on achieving a complete response rate, and treating intermediate, poor-risk disease where she describes an excitin...
|
- Details
- Monty Pal joins Petros Grivas to share highlights from his ASCO 2019 presentation on IMmotion150, a phase two clinical trial in kidney cancer looking at patient-reported outcomes, that compared monotherapy with atezolizumab, to sunitinib, to the combination of bevacizumab with atezolizumab, a unique opportunity to look at monotherapy in this setting. Biographies: Sumanta Kumar Pal, MD , Associate...
|
- Details
- Tian Zhang and Alicia Morgans discuss the three new approvals for the first line treatment of metastatic renal cell carcinoma, including cabozantinib with targeted agents, IO combinations with ipilimumab and nivolumab and now the recent approval of pembrolizumab plus axitinib. Dr. Zhang reviews the long-term follow-up from the CHECKMATE-214 study along with the CABOSUN data. The discussion conclud...
|
